<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
 <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Biology and life sciences : Organisms :"/>
 <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
 <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
 <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
 <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
 <result pre="Sciences : Biochemistry : Proteins : Immune System Proteins: Antibodies" exact="Chikungunya" post="as a paradigm for emerging viral diseases: Evaluating disease"/>
 <result pre="viral diseases: Evaluating disease impact and hurdles to vaccine development" exact="Chikungunya" post="fever disease impact and vaccine development RezzaGiovanni1http://orcid.org/0000-0001-8016-8556WeaverScott C.2*[1], Department"/>
 <result pre="medium, provided the original author and source are credited.pntd.0006919.pdf Abstract" exact="Chikungunya" post="fever (CHIKF) is an emerging infectious disease caused by"/>
 <result pre="received no specific funding for this work. fig-count: table-count: page-count:" exact="Chikungunya" post="virus (CHIKV) is an RNA alphavirus belonging to the"/>
 <result pre="identified in Tanzania in 1952. During epidemics and endemic circulation," exact="CHIKV" post="is transmitted by Aedes aegypti and, to a lesser"/>
 <result pre="to a lesser extent, by A. albopictus mosquitoes. Infection with" exact="CHIKV" post="typically causes a self-limiting febrile illness, chikungunya fever (CHIKF),"/>
 <result pre="involve severe neurologic sequelae in fetuses and infants [1, 2]." exact="CHIKV" post="is enzootic in Africa, where transmission involves different arboreal"/>
 <result pre="probably occur in many regions of Sub-Saharan Africa. In Asia," exact="CHIKV" post="is endemic and causes recurrent and sometimes large epidemics,"/>
 <result pre="the Indian subcontinent and in Southeast Asia [1–3]. In 2004," exact="CHIKV" post="reemerged to cause large outbreaks, which began on the"/>
 <result pre="[6]. In 2013, autochthonous (locally originating) chains of transmission of" exact="CHIKV" post="were identified for the first time in the Americas"/>
 <result pre="were identified for the first time in the Americas [7]." exact="CHIKV" post="has expanded its range of activity to include temperate"/>
 <result pre="of CHIKF were reported (http://www.who.int/denguecontrol/arbo-viral/other_arboviral_chikungunya/en/). Furthermore, the global impact of" exact="CHIKV" post="is constantly growing, due to the introduction and spread"/>
 <result pre="cases, a completely naïve population (Fig 1). The capacity of" exact="CHIKV" post="to adapt to a new mosquito vector has been"/>
 <result pre="World map with countries where autochthonous (locally initiated) chains of" exact="CHIKV" post="transmission have been identified. Data from World Health Organization"/>
 <result pre="Indian outbreaks [1], and fatal encephalitis has been reported with" exact="CHIKV" post="infection both in Italy [8] and in La Reunion,"/>
 <result pre="[20]. These findings provide evidence of severe disease associated with" exact="CHIKV" post="infection, which may have a high impact in terms"/>
 <result pre="mosquito-borne viruses such as dengue, Zika, and even yellow fever," exact="CHIKV" post="typically causes symptomatic infection, and consequently outbreaks are accompanied"/>
 <result pre="Unfortunately, little information is available on the economic costs of" exact="CHIKV" post="infection. Healthcare costs during the La Reunion in 2005"/>
 <result pre="live-attenuated candidates, genetically engineered complementary DNA (cDNA) clone-based, rationally attenuated" exact="CHIKV" post="strains were more recently developed and successfully tested in"/>
 <result pre="employed a picornavirus-derived internal ribosome entry site to replace the" exact="CHIKV" post="subgenomic promoter [41]. This replacement is highly stable after"/>
 <result pre="neutralizing antibody responses and protects mice and NHPs against virulent" exact="CHIKV" post="challenge, including weight change, fever, and viremia in cynomolgus"/>
 <result pre="this Indian Ocean lineage-derived strain also extends to Asian/American lineage" exact="CHIKV" post="strains [43]. Other clone-derived, rationally attenuated CHIKF vaccine candidates"/>
 <result pre="Medical Research Institute of Infectious Diseases, University of Maryland Live-attenuated" exact="CHIKV" post="strain 1 Completed Phase 2 [32, 33] VRC-CHKVLP059-00-VP (PXVX0317"/>
 <result pre="US National Institutes of Health, PaxVax Virus-like particle assembled from" exact="CHIKV" post="proteins expressed in mammalian cells 2 Phase 2 (NCT02562482,"/>
 <result pre="Inst. Pasteur, Themis Bioscience Recombinant live- attenuated measles vaccine expressing" exact="CHIKV" post="virus-like particles derived from the structural protein genes 2"/>
 <result pre="Phase 2 (NCT03101111, NCT02861586) [44, 63] VLA1553 Valneva, Austria Recombinant" exact="CHIKV" post="with nsP3 deletion 1 Recruiting for Phase 1 (NCT03382964)"/>
 <result pre="1 (NCT03382964) [38, 64] VAL-181388 Moderna Therapeutics mRNA encoding the" exact="CHIKV" post="structural proteins Not reported Recruiting for Phase 1 (NCT03325075)"/>
 <result pre="[58] CHIKV/IRES University of Texas Medical Branch, Takeda Pharmaceuticals Recombinant" exact="CHIKV" post="with subgenomic promoter replaced by internal ribosome entry site"/>
 <result pre="attenuated measles virus strain as a vector to express the" exact="CHIKV" post="structural proteins [44]. In a Phase 1 trial, this"/>
 <result pre="clinical trials. Expression via electroporation of mammalian cells of the" exact="CHIKV" post="structural polyprotein ORF in a DNA plasmid form produces"/>
 <result pre="These VLPs elicit neutralizing antibodies against envelope proteins from diverse" exact="CHIKV" post="strains, and immunized NHPs produce high-titer neutralizing antibodies that"/>
 <result pre="(Table 1). Nucleic acid-based vaccines Finally, nucleic acid-based vaccines against" exact="CHIKV" post="are under development. These vaccines have clear advantages, from"/>
 <result pre="proven safety records. However, based on initial results with DNA" exact="Zika" post="vaccines that were generated within a few months of"/>
 <result pre="generated within a few months of the recognition of congenital" exact="Zika" post="Syndrome, these vaccines require multiple doses and immunity is"/>
 <result pre="include cities with histories of recurrent dengue outbreaks (dengue and" exact="CHIKV" post="share the same human-amplified transmission cycles, so regions susceptible"/>
 <result pre="impossible to realize [57]. For example, if human antibodies against" exact="CHIKV" post="developed from individuals vaccinated in phase 1 and 2"/>
 <result pre="58]. Although there is strong evidence that neutralizing antibodies against" exact="CHIKV" post="protect against infection and disease, the lack of compete"/>
 <result pre="[62]. Conclusion In summary, the burden of disease caused by" exact="CHIKV" post="is very high, due to the expanding geographic range"/>
 <result pre="stakeholders. Key learning points The burden of disease due to" exact="CHIKV" post="is high due to recurrent epidemics and outbreaks in"/>
 <result pre="due to recurrent epidemics and outbreaks in previously CHIKV-free areas" exact="CHIKV" post="causes a major public health impact, especially due to"/>
 <result pre="that can be highly debilitating Because mosquito control programs against" exact="CHIKV" post="vectors have limited efficacy in controlling transmission, an effective"/>
 <result pre="2014/08/19. doi: 10.1016/S0140-6736(14)61185-5. PubMed PMID: 25132507. Weaver SC, Lecuit M." exact="Chikungunya" post="virus and the global spread of a mosquito-borne disease."/>
 <result pre="considerations in development of vaccines to prevent disease caused by" exact="Chikungunya" post="virus. Vaccine. 2017;35(37):4851–8. doi: 10.1016/j.vaccine.2017.07.065. PubMed PMID: 28760614. References"/>
 <result pre="arbovirosis. The Lancet infect. Dis. 2007;7(5):319–27. 10.1016/S1473-3099(07)70107-X .17448935 2WeaverSC, LecuitM." exact="Chikungunya" post="virus and the global spread of a mosquito-borne disease."/>
 <result pre="2006. WHO Weekly Epidemiol. Record. 2006;81:105–116. 5CharrelRN, de LamballerieX, RaoultD." exact="Chikungunya" post="outbreaks—the globalization of vectorborne diseases. N Engl J Med."/>
 <result pre="El-SawafG, FaggioniG, VescioF, Al AmeriR, De SantisR, et al.Co-circulation of" exact="Dengue" post="and Chikungunya Viruses, Al Hudaydah, Yemen, 2012. Emerg infect"/>
 <result pre="VescioF, Al AmeriR, De SantisR, et al.Co-circulation of Dengue and" exact="Chikungunya" post="Viruses, Al Hudaydah, Yemen, 2012. Emerg infect Dis. 2014;20(8):1351–4."/>
 <result pre="2018 Dec 21]. 11ErasmusJH, RossiSL, WeaverSC. Development of Vaccines for" exact="Chikungunya" post="Fever. J Infect Dis. 2016;214(suppl 5):S488–S96. 10.1093/infdis/jiw27127920179 12PowersAM. Vaccine"/>
 <result pre="2016;214(suppl 5):S488–S96. 10.1093/infdis/jiw27127920179 12PowersAM. Vaccine and Therapeutic Options To Control" exact="Chikungunya" post="Virus. Clinical microbiology reviews. 2018;31(1). 10.1128/CMR.00104-16 .29237708 13YangS, FinkD,"/>
 <result pre="considerations in development of vaccines to prevent disease caused by" exact="Chikungunya" post="virus. Vaccine. 2017;35(37):4851–8. 10.1016/j.vaccine.2017.07.065 .28760614 14TsetsarkinKA, ChenR, WeaverSC. Interspecies"/>
 <result pre="mapping. Euro Surveill. 2008;13(7). Epub 2008/05/01. .18445418 18ArpinoC, CuratoloP, RezzaG." exact="Chikungunya" post="and the nervous system: what we do and do"/>
 <result pre="SookhareeaC, et al.Increase in cases of Guillain-Barre syndrome during a" exact="Chikungunya" post="outbreak, French Polynesia, 2014 to 2015. Euro Surveill. 2015;20(48):3007910.2807/1560-7917.ES.2015.20.48.30079"/>
 <result pre="10.1016/S1473-3099(07)70294-3 .18156079 22SissokoD, MalvyD, EzzedineK, RenaultP, MoscettiF, LedransM, et al.Post-epidemic" exact="Chikungunya" post="disease on Reunion Island: course of rheumatic manifestations and"/>
 <result pre="10.1016/j.jinf.2012.04.005 .22522292 25SoumahoroMK, BoellePY, GauzereBA, AtsouK, PelatC, LambertB, et al.The" exact="Chikungunya" post="epidemic on La Reunion Island in 2005–2006: a cost-of-illness"/>
 <result pre="burden of dengue and chikungunya from the Americas to Asia." exact="Dengue" post="Bulletin 2010; 34. WHO Regional Office for South-East Asia,"/>
 <result pre="New Haven EliScholar, USA: Yale University; 2016. 28EckelsKH, HarrisonVR, HetrickFM." exact="Chikungunya" post="virus vaccine prepared by Tween-ether extraction. Appl Microbiol. 1970;19(2):321–5."/>
 <result pre="29HarrisonVR, EckelsKH, BartelloniPJ, HamptonC. Production and evaluation of a formalin-killed" exact="Chikungunya" post="vaccine. J Immunol. 1971;107(3):643–7. Epub 1971/09/01. .4999088 30TiwariM, ParidaM,"/>
 <result pre="adapted formalin inactivated vaccine derived from novel ECSA genotype of" exact="Chikungunya" post="virus. Vaccine. 2009;27(18):2513–22. 10.1016/j.vaccine.2009.02.062 .19368794 31KumarM, SudeepAB, ArankalleVA. Evaluation"/>
 <result pre=".11304054 34GorchakovR, WangE, LealG, ForresterNL, PlanteK, RossiSL, et al.Attenuation of" exact="Chikungunya" post="virus vaccine strain 181/clone 25 is determined by two"/>
 <result pre="J Infect Dis. 1998;177(3):634–41. 9498442 36WeaverSC, OsorioJE, LivengoodJA, ChenR, StinchcombDT." exact="Chikungunya" post="virus and prospects for a vaccine. Expert Rev Vaccines."/>
 <result pre="a vaccine. Expert Rev Vaccines. 2012;11(9):1087–101. Epub 2012/11/16. 10.1586/erv.12.8423151166 37PowersAM." exact="Chikungunya" post="virus control: is a vaccine on the horizon?Lancet. 2014"/>
 <result pre=".25132506 38HallengardD, KakoulidouM, LullaA, KummererBM, JohanssonDX, MutsoM, et al.Novel attenuated" exact="Chikungunya" post="vaccine candidates elicit protective immunity in C57BL/6 mice. J"/>
 <result pre="of adaptive immunity to CHIKV/IRES a novel candidate vaccine against" exact="Chikungunya" post="in the A129 mouse model. Vaccine. 2013;31(33):3353–60. Epub 2013/06/04."/>
 <result pre="Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated" exact="Chikungunya" post="Vaccine Candidate. PLoS Negl Trop Dis. 2015;9(9):e000400710.1371/journal.pntd.000400726340754 43LangsjoenRM, HallerSL,"/>
 <result pre="al.Utilization of an Eilat Virus-Based Chimera for Serological Detection of" exact="Chikungunya" post="Infection. PLoS Negl Trop Dis. 2015;9(10):e000411910.1371/journal.pntd.000411926492074 48ErasmusJH, AugusteAJ, KaelberJT,"/>
 <result pre="SunS, HoldawayHA, KongWP, et al.A virus-like particle vaccine for epidemic" exact="Chikungunya" post="virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334–8."/>
 <result pre="chikungunya virus. Vaccine Development and Therapy. 2013;3:35–46. 54WhiteheadSS, SubbaraoK. Which" exact="Dengue" post="Vaccine Approach Is the Most Promising, and Should We"/>
 <result pre="Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to" exact="Dengue" post="Virus Revealed by Vaccination. Cold Spring Harb Perspect Biol."/>
 <result pre="against chikungunya?Pathog Glob Health. 2015;109(4):170–3. 10.1179/2047773215Y.000000001725971340 61RezzaG. Vaccines against chikungunya," exact="Zika" post="and other emerging Aedes mosquito-borne viruses: unblocking existing bottlenecks."/>
 <result pre="LumFM, KummererBM, LullaA, LullaV, Garcia-ArriazaJ, et al.Prime-boost immunization strategies against" exact="Chikungunya" post="virus. J Virol. 2014;88(22):13333–43. 10.1128/JVI.01926-1425210177 65Chikungunya: Villepin refuse la"/>
</results>
